The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ProSperA: Phase I study to evaluate safety, tolerability and preliminary efficacy of a bispecific PSMAxCD3 antibody in men with biochemical recurrence of prostate cancer.
 
Christopher Hackenbruch
No Relationships to Disclose
 
Jonas S. Heitmann
Travel, Accommodations, Expenses - Synimmune
 
Juliane S. Walz
Research Funding - GlaxoSmithKline; Roche Pharma AG
Patents, Royalties, Other Intellectual Property - CoVac-1 peptide cocktail, Application number: PCT/EP 20 190 070.1; Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar HCCand other cancers, Application number: EP 2121472; SARS-CoV-2 CD8+ und CD4+ T cell epitopes, Application number: PCT/EP 20 169 047.6
 
Birgit Federmann
No Relationships to Disclose
 
Martin Pflügler
No Relationships to Disclose
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Amgen; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Janssen
 
Gundram Jung
Stock and Other Ownership Interests - CureVac; Immatics
Consulting or Advisory Role - Cullinan Oncology
Patents, Royalties, Other Intellectual Property - An optimized ACE2 fusion protein with improved activity against SARS-CoV-2 variants (ACE2 fusion protein)EP 22198499.0
 
Helmut R. Salih
Stock and Other Ownership Interests - Immatics
Consulting or Advisory Role - Novartis; Pfizer; Philogen; Synimmune
Research Funding - ABL Bio
Patents, Royalties, Other Intellectual Property - Inventor on several patents in the field of caner immunotherapy
(OPTIONAL) Uncompensated Relationships - TWYCE GmbH